<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; by</title>
	<atom:link href="http://www.tapanray.in/tag/by/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>India: Too Enticing a Pharma Market to Ignore by the Global Players despite unhappiness</title>
		<link>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness</link>
		<comments>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/#comments</comments>
		<pubDate>Mon, 22 Oct 2012 00:00:36 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[despite]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Enticing]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[Ignore]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Too]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[unhappiness]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=1078</guid>
		<description><![CDATA[A White-Paper, titled “Emerging Markets Today and Tomorrow: Insights on Healthcare, Pharmaceuticals and Future Trends in the BRIC Landscape”, released by a global technology and services company specializing in healthcare, Cegedim, in June, 2012 highlighted that 20 to 30 percent &#8230; <a href="http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/india-too-enticing-a-pharma-market-to-ignore-by-the-global-players-despite-unhappiness/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Nutraceuticals with Therapeutic Claims: A Vulnerable Growing Bubble Protected by Faith and Hope of Patients</title>
		<link>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients</link>
		<comments>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/#comments</comments>
		<pubDate>Mon, 27 Aug 2012 00:00:39 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Biotech]]></category>
		<category><![CDATA[Bubble]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Claims]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Compulsory Licensing]]></category>
		<category><![CDATA[Counterfeit]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Ethical Marketing]]></category>
		<category><![CDATA[Faith]]></category>
		<category><![CDATA[FDI]]></category>
		<category><![CDATA[glaxo]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hope]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[kopran]]></category>
		<category><![CDATA[Legal]]></category>
		<category><![CDATA[Medical Diagnostics]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Neutraceutical]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[OPPI]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Protected]]></category>
		<category><![CDATA[RDP]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research & Development]]></category>
		<category><![CDATA[sami]]></category>
		<category><![CDATA[Spurious]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[Vulnerable]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=45</guid>
		<description><![CDATA[Today a growing number of particularly the aging population wants to live a healthy life without consuming much of chemical drugs, which in turn is becoming a key growth driver for nutraceutical products across the world. Further, increasing interest towards &#8230; <a href="http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/nutraceuticals-with-therapeutic-claims-a-vulnerable-growing-bubble-protected-by-faith-and-hope-of-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Finance Ministry Disallows Expenses on &#8216;Freebies&#8217; to Doctors by Pharma Companies in line with MCI Guidelines: A Possible Game Changer?</title>
		<link>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer</link>
		<comments>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/#comments</comments>
		<pubDate>Mon, 06 Aug 2012 00:00:12 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Disallows]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Expenses]]></category>
		<category><![CDATA[Finance]]></category>
		<category><![CDATA[Freebies]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Guidelines]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[Ministry]]></category>
		<category><![CDATA[on]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Possible]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=56</guid>
		<description><![CDATA[Things are unfolding reasonably faster now related to the financial relationship between the pharmaceutical companies and the medical profession. All these issues are getting increasingly dragged into the public debate where government can no longer play the role of a &#8230; <a href="http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/finance-ministry-disallows-expenses-on-freebies-to-doctors-by-pharma-companies-in-line-with-mci-guidelines-a-possible-game-changer/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>First ever &#8216;Code of Pharma Marketing Practices&#8217; by the Government: A strong signal to &#8220;Shape Up&#8221;!</title>
		<link>http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up</link>
		<comments>http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/#comments</comments>
		<pubDate>Mon, 18 Jul 2011 00:00:34 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[ever]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[of pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Shape]]></category>
		<category><![CDATA[signal]]></category>
		<category><![CDATA[Strong]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Up]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=227</guid>
		<description><![CDATA[After a protracted debate on the alleged ‘unethical marketing practices’ by the pharmaceutical companies, in May 2011, the Department of Pharmaceuticals (DoP) came out with a draft ‘Uniform Code of Pharmaceutical Marketing Practices (UCMP)’ to address this issue squarely and &#8230; <a href="http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/first-ever-code-of-pharma-marketing-practices-by-the-government-a-strong-signal-to-shape-up/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Indian Pharmaceutical Industry could well be a contender for global supremacy by the next decade, competing effectively with China</title>
		<link>http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china</link>
		<comments>http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/#comments</comments>
		<pubDate>Mon, 22 Nov 2010 00:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[ANDA]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[competing]]></category>
		<category><![CDATA[contender]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[CRAM]]></category>
		<category><![CDATA[decade]]></category>
		<category><![CDATA[DMF]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[effectively]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[next]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[refor]]></category>
		<category><![CDATA[supremacy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[well]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=345</guid>
		<description><![CDATA[By the next decade of this millennium both India and China are expected to be the top two emerging markets of the world in the pharmaceutical sector, registering a scorching pace of growth all around. The quality of consistency and &#8230; <a href="http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/indian-pharmaceutical-industry-could-well-be-a-contender-for-global-supremacy-by-the-next-decade-competing-effectively-with-china/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Prescribing medicines by generic names…a good intent… but is it a practical proposition in India?</title>
		<link>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india</link>
		<comments>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/#comments</comments>
		<pubDate>Mon, 06 Sep 2010 00:30:32 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[But]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[chemists]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[intent]]></category>
		<category><![CDATA[is]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[name]]></category>
		<category><![CDATA[names]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practical]]></category>
		<category><![CDATA[Prescribing]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[proposition]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=378</guid>
		<description><![CDATA[Parliamentary Standing Committee for Health and Family Welfare in their recommendation to the ‘Rajya Sabha’ of the Indian Parliament on August 4, 2010, recommended prescription of medicines by their generic names. This recommendation appears to be based on the premises &#8230; <a href="http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/prescribing-medicines-by-generic-namesa-good-intent-but-is-it-a-practical-proposition-in-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The First Pharmaceuticals Census of India – a commendable initiative by the National Pharmaceutical Pricing Authority (NPPA)</title>
		<link>http://www.tapanray.in/the-first-pharmaceuticals-census-of-india-a-commendable-initiative-by-the-national-pharmaceutical-pricing-authority-nppa/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-first-pharmaceuticals-census-of-india-a-commendable-initiative-by-the-national-pharmaceutical-pricing-authority-nppa</link>
		<comments>http://www.tapanray.in/the-first-pharmaceuticals-census-of-india-a-commendable-initiative-by-the-national-pharmaceutical-pricing-authority-nppa/#comments</comments>
		<pubDate>Mon, 12 Jul 2010 01:00:57 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Authority]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Census]]></category>
		<category><![CDATA[commendable]]></category>
		<category><![CDATA[First]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NPPA]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=403</guid>
		<description><![CDATA[Currently there is indeed a crying need for the pharmaceutical industry to generate a robust data base to formulate not only various healthcare related policies, but also to measure the level of their effective implementation. In the absence of such &#8230; <a href="http://www.tapanray.in/the-first-pharmaceuticals-census-of-india-a-commendable-initiative-by-the-national-pharmaceutical-pricing-authority-nppa/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-first-pharmaceuticals-census-of-india-a-commendable-initiative-by-the-national-pharmaceutical-pricing-authority-nppa/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Amendment of &#8216;Professional Conduct, Etiquette and Ethics&#8217; Regulations for the Doctors by the MCI could dramatically change the Pharmaceutical Marketing Practices in India, hereafter.</title>
		<link>http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter</link>
		<comments>http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/#comments</comments>
		<pubDate>Mon, 11 Jan 2010 01:00:43 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Code]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Conduct]]></category>
		<category><![CDATA[could]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[dramatically]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[Etiquette]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[hereafter]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MCI]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[Professional]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=485</guid>
		<description><![CDATA[As reported in the media, the notification of the Medical Council of India (MCI) dated December 10, 2009 amending the &#8220;Indian Medical Council (Professional Conduct, Etiquette and Ethics), Regulations 2002&#8243; has been welcomed by the medical profession. Areas of stricter &#8230; <a href="http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/amendment-of-professional-conduct-etiquette-and-ethics-regulations-for-the-doctors-by-the-mci-could-dramatically-change-the-pharmaceutical-marketing-practices-in-india-hereafter/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Open Source Drug Discovery (OSDD) initiative for the tropical diseases by CSIR and cancer by GlaxoSmithKline deserves a big applaud and support from all concerned.</title>
		<link>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned</link>
		<comments>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/#comments</comments>
		<pubDate>Thu, 03 Dec 2009 01:00:31 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[All]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[applaud]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[concerned]]></category>
		<category><![CDATA[CSIR]]></category>
		<category><![CDATA[deserves]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[for]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Initiative]]></category>
		<category><![CDATA[OSDD]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pool. Open]]></category>
		<category><![CDATA[poor]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[source]]></category>
		<category><![CDATA[support]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[tropical]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=709</guid>
		<description><![CDATA[As the name suggest the ‘Open Source Drug Discovery (OSDD)’ is an open source code model of discovering a New Chemical Entity (NCE) or a New Molecular Entity (NME). In this model all data generated related to the discovery research will be &#8230; <a href="http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/open-source-drug-discovery-osdd-initiative-for-the-tropical-diseases-by-csir-and-cancer-by-glaxosmithkline-deserves-a-big-applaud-and-support-from-all-concerned/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Will mandatory disclosure of ‘payments to physicians’ by the pharmaceutical companies be an overall part of “Healthcare reform process” in the US and what about India?</title>
		<link>http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india</link>
		<comments>http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/#comments</comments>
		<pubDate>Thu, 12 Nov 2009 01:00:21 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[about]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[be]]></category>
		<category><![CDATA[by]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[overall]]></category>
		<category><![CDATA[part]]></category>
		<category><![CDATA[payments]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[physicians]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[what]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=727</guid>
		<description><![CDATA[The brief Scenario in India: In India over 20, 000 pharmaceutical companies of varying size and scale of operations are currently operating. It is alleged that lack of regulatory scrutiny is prompting many of these companies to adapt to ‘free-for-all’ &#8230; <a href="http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/will-mandatory-disclosure-of-payments-to-physicians-by-the-pharmaceutical-companies-be-an-overall-part-of-healthcare-reform-process-in-the-us-and-what-about-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
